KA
VRTX icon

Klingman & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Klingman & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$236K Buy
529
+64
+14% +$29.8K 0.01% 298
2025
Q4 		$211K Buy
+465
New +$200K 0.01% 312
2025
Q3 		– Sell
-466
Closed -$207K – 340
2025
Q2 		$207K Buy
+466
New +$215K 0.01% 297

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Klingman & Associates's VRTX Position: Q1 2026 in Review

Klingman & Associates increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q1 2026, buying an estimated $29.8K and bringing the position to 529 shares worth $236K. The position accounts for 0.01% of the portfolio, ranked #298.

Klingman & Associates first reported a position in VRTX in Q2 2025 and has held it in 3 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Klingman & Associates held 529 shares of Vertex Pharmaceuticals worth $236K as of Q1 2026.
  • Klingman & Associates bought 64 Vertex Pharmaceuticals shares in Q1 2026, an estimated $29.8K.
  • Vertex Pharmaceuticals made up 0.01% of Klingman & Associates's portfolio in Q1 2026, its #298 holding.
  • Klingman & Associates first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Klingman & Associates's 13F filing for Q1 2026, filed 14 May 2026.